Deepti Anbarasan, MD

Research Update

How Do We Help Depressed Smokers Quit?

October 1, 2024

Justin Morales, MD and Deepti Anbarasan, MD

Justin Morales, MD, and Deepti Anbarasan, MD. Drs. Morales and Anbarasan have no financial relationships with companies related to this material.

Tobacco smoking and major depression are highly comorbid, and depressed patients usually have a tougher time quitting than their non-depressed counterparts. In this research study, investigators compared the efficacy of anti-smoking medications in those with depression. The results may surprise you.

Clinical Update

A Personalized Approach to Antidepressant Augmentation

April 1, 2024

Deepti Anbarasan, MD and David Liebers, MD

Deepti Anbarasan, MD. Associate Professor, Psychiatry and Neurology, New York University, New York, NY.

David Liebers, MD. Psychiatry resident at NYU Langone Department of Psychiatry.

The authors have no financial relationships with companies related to this material.

The best augmentation strategy varies by patient. Learn which features help personalize the plan.

Research Update

Are Higher-Potency Cannabis Products Riskier for Mental Illness?

April 1, 2023

Deepti Anbarasan, MD and John Wang, MD

John Wang, MD, and Deepti Anbarasan, MD. Dr. Wang and Dr. Anbarasan have no financial relationships with companies related to this material.

In recent years, cannabis with widely varying THC concentrations has become available. But is there a link between how much THC a cannabis product contains and its risk of adverse effects. Researchers here add to the mounting evidence that the answer is likely yes.

CLINICAL UPDATE

Misuse of Legally Available Substances in Adolescents and Teens

January 30, 2023

Deepti Anbarasan, MD and Eric Whitney, MD, MSEd

Eric Whitney, MD, MSEd. Clinical Instructor, Child and Adolescent Psychiatry Fellow, NYU Grossman School of Medicine. New York, NY.

Deepti Anbarasan, MD. Associate Professor, Psychiatry & Neurology, New York University. New York, NY.

Dr. Whitney and Dr. Anbarasan have no financial relationships with companies related to this material.

This clinical update covers the psychogenic effects and risks of four readily accessible, legally available, and commonly misused over-the-counter medications. Our patients misuse these medications which have potential for real harm, including drug-drug interactions with prescribed medications.

Supervised Drug Consumption

July 1, 2022

Deepti Anbarasan, MD and Christopher Clayton, MD, EdM

Christopher L. Clayton, MD, EdM. PGY-4 psychiatry resident, NYU Gorssman School of Medicine, New York, NY. Deepti Anbarasan, MD. Associate Professor in Psychiatry and Neurology, New York University, New York, NY.

Dr. Clayton and Dr. Anbarasan, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Supervised Consumption Sites are clinical settings where patients can use drugs in as safe a manner as possible. Clients are supplied with sterile equipment and the clinics are staffed by medical professionals who can respond in the case of an overdose. Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

Misuse of Over-the-Counter Medications

September 10, 2021

Amy Ton, MD, and Deepti Anbarasan, MD

Amy Ton, MD, resident in psychiatry, New York University, New York, NY. Deepti Anbarasan, MD, associate professor in psychiatry & neurology, New York University. Dr. Ton and Dr. Anbarasan have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Over the counter medications are commonly misused, particularly among younger patients. Dextromethorphan, first generation antihistamines, and nasal decongestants are the most frequently encountered. We cover the clinical features of each and discuss treatment strategies.